Advertisement
U.S. markets closed

Mustang Bio, Inc. (MBIO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
0.2051-0.0028 (-1.35%)
At close: 04:00PM EST
0.2100 +0.00 (+2.39%)
After hours: 07:57PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.2079
Open0.2030
Bid0.1473 x 200
Ask0.2626 x 200
Day's Range0.2020 - 0.2122
52 Week Range0.1280 - 1.6780
Volume402,144
Avg. Volume1,864,317
Market Cap9.8M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.3300
Earnings DateNov 08, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Mustang Bio Receives Positive Listing Determination from Nasdaq

    WORCESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced that by decision dated November 8, 2024, the Nasdaq Hearings Panel granted the Company’s request for an extension to evidence compliance with all applicable criteria for continued listing on The Nasdaq

  • Pharmaceutical Technology

    Mustang Bio’s MB-108 receives FDA orphan drug status for glioma treatment

    The ongoing Phase I trial of MB-108 at the University of Alabama at Birmingham is enrolling patients.